These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

651 related items for PubMed ID: 11592341

  • 1. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
    Supko JG, Garcia-Carbonero R, Puchalski TA, Malspeis L.
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
    [Abstract] [Full Text] [Related]

  • 2. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
    Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH, Batist G, Patenaude F, Bangash N, Panarello L, Alaoui-Jamali M, Sausville E.
    J Clin Oncol; 2003 Jan 15; 21(2):232-40. PubMed ID: 12525514
    [Abstract] [Full Text] [Related]

  • 3. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
    Marcantonio D, Panasci LC, Hollingshead MG, Alley MC, Camalier RF, Sausville EA, Dykes DJ, Carter CA, Malspeis L.
    Cancer Res; 1997 Sep 15; 57(18):3895-8. PubMed ID: 9307267
    [Abstract] [Full Text] [Related]

  • 4. Specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea in plasma.
    Supko JG, Phillips LR, Malspeis L.
    J Chromatogr B Biomed Appl; 1996 Mar 03; 677(2):351-62. PubMed ID: 8704941
    [Abstract] [Full Text] [Related]

  • 5. Relationship between drug delivery and the intra-arterial infusion rate of SarCNU in C6 rat brain tumor model.
    Takeda N, Diksic M.
    J Neurooncol; 1999 Feb 03; 41(3):235-46. PubMed ID: 10359143
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells.
    Skalski V, Yarosh DB, Batist G, Gros P, Feindel W, Kopriva D, Panasci LC.
    Mol Pharmacol; 1990 Sep 03; 38(3):299-305. PubMed ID: 2402223
    [Abstract] [Full Text] [Related]

  • 7. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system.
    Noë AJ, Malapetsa A, Panasci LC.
    Mol Pharmacol; 1993 Jul 03; 44(1):204-9. PubMed ID: 8341272
    [Abstract] [Full Text] [Related]

  • 8. Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics.
    Noë AJ, Malapetsa A, Panasci LC.
    Cancer Res; 1994 Mar 15; 54(6):1491-6. PubMed ID: 8137253
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
    Huynh H, Nguyen TH, Panasci L, Do P.
    Cancer; 2004 Dec 15; 101(12):2881-91. PubMed ID: 15529313
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys.
    Chen Y, Amantana A, Tyavanagimatt SR, Zima D, Yan XS, Kasi G, Weeks M, Stone MA, Weimers WC, Samuel P, Tan Y, Jones KF, Lee DR, Kickner SS, Saville BM, Lauzon M, McIntyre A, Honeychurch KM, Jordan R, Hruby DE, Leeds JM.
    PLoS One; 2011 Dec 15; 6(8):e23237. PubMed ID: 21858040
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.